Iterum Therapeutics PLC
NASDAQ:ITRM
Iterum Therapeutics PLC
Total Current Assets
Iterum Therapeutics PLC
Total Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Iterum Therapeutics PLC
NASDAQ:ITRM
|
Total Current Assets
$13.7m
|
CAGR 3-Years
-41%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
Perrigo Company PLC
NYSE:PRGO
|
Total Current Assets
$2.9B
|
CAGR 3-Years
4%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
0%
|
|
|
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
|
Total Current Assets
$3.8B
|
CAGR 3-Years
13%
|
CAGR 5-Years
8%
|
CAGR 10-Years
11%
|
|
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
Total Current Assets
$172.2m
|
CAGR 3-Years
15%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
3%
|
|
|
G
|
GH Research PLC
NASDAQ:GHRS
|
Total Current Assets
$286m
|
CAGR 3-Years
19%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Cosmo Pharmaceuticals NV
SIX:COPN
|
Total Current Assets
€187.2m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-2%
|
|
Iterum Therapeutics PLC
Glance View
Iterum Therapeutics Plc operates as a pharmaceutical company, which engages in the development and commercialization of sulopenem to be potentially the first and only oral and intravenous (IV) branded penem available. The company is headquartered in Dublin, Dublin and currently employs 13 full-time employees. The company went IPO on 2018-05-25. The firm is focused on developing significantly differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant (MDR) pathogens. The firm is developing sulopenem - the oral and intervenous (IV) penem antibiotic demonstrating a potent spectrum of activity against multi-drug resistant gram-negative. The company is a bioavailable, antibiotic covering gram-positive, gram-negative and anaerobic pathogen with in-vitro activity against multidrug-resistant pathogens, including Extended-Spectrum Beta-Lactamase (ESBL)-producing Escherichia, coli and Klebsiella and pneumonia. The firm also developed sulopenem in an oral tablet formulation, sulopenem etzadroxil-probenecid, which is known as oral sulopenem.
See Also
What is Iterum Therapeutics PLC's Total Current Assets?
Total Current Assets
13.7m
USD
Based on the financial report for Sep 30, 2025, Iterum Therapeutics PLC's Total Current Assets amounts to 13.7m USD.
What is Iterum Therapeutics PLC's Total Current Assets growth rate?
Total Current Assets CAGR 5Y
3%
Over the last year, the Total Current Assets growth was -14%. The average annual Total Current Assets growth rates for Iterum Therapeutics PLC have been -41% over the past three years , 3% over the past five years .
